Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort Safety Study in Asthma
NCT01444430Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2011
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of budesonide in asthma (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization) at 27 weeks and Number of Participants Experiencing an Event Included in the Definition of Asthma Exacerbation at 26 weeks. Started Dec 2011; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01444430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01444430.